Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Campia

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Environment International|February 6, 2017
Chemical alternatives assessment of different flame retardants - A case study including multi-walled carbon nanotubes as synergistKarin Aschberger, Ivana Campia, Laia Quiros Pesudo, et al.
Applied in Vitro Toxicology|July 31, 2018
Creating a Structured AOP Knowledgebase via Ontology-Based AnnotationsCataia Ives, Ivana Campia, Rong-Lin Wang, et al.
Toxicology and Applied Pharmacology|August 4, 2009
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cellsChiara Riganti, Ivana Campia, Manuela Polimeni, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 10, 2026
Corrigendum to 'A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells' [Journal of Controlled Release 149(2) (2011) 196-205]Joanna Kopecka, Ivana Campia, Paolo Olivero, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 16, 2010
A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cellsJoanna Kopecka, Ivana Campia, Paolo Olivero, et al.
Current Drug Metabolism|July 23, 2013
Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrierMartha Leonor Pinzón-Daza, Ivana Campia, Joanna Kopecka, et al.
Current Drug Metabolism|October 16, 2008
Classical inhibitors of NOX NAD(P)H oxidases are not specificElisabetta Aldieri, Chiara Riganti, Manuela Polimeni, et al.
Oncotarget|December 30, 2014
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesotheliomaIris Chiara Salaroglio, Ivana Campia, Joanna Kopecka, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|July 16, 2013
Insights in the chemical components of liposomes responsible for P-glycoprotein inhibitionJoanna Kopecka, Giuseppina Salzano, Ivana Campia, et al.
Oncotarget|February 18, 2015
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cellsJoanna Kopecka, Ivana Campia, Andrea Jacobs, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Environment International|February 6, 2017
Chemical alternatives assessment of different flame retardants - A case study including multi-walled carbon nanotubes as synergistKarin Aschberger, Ivana Campia, Laia Quiros Pesudo, et al.
Applied in Vitro Toxicology|July 31, 2018
Creating a Structured AOP Knowledgebase via Ontology-Based AnnotationsCataia Ives, Ivana Campia, Rong-Lin Wang, et al.
Toxicology and Applied Pharmacology|August 4, 2009
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cellsChiara Riganti, Ivana Campia, Manuela Polimeni, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 10, 2026
Corrigendum to 'A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells' [Journal of Controlled Release 149(2) (2011) 196-205]Joanna Kopecka, Ivana Campia, Paolo Olivero, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 16, 2010
A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cellsJoanna Kopecka, Ivana Campia, Paolo Olivero, et al.
Current Drug Metabolism|July 23, 2013
Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrierMartha Leonor Pinzón-Daza, Ivana Campia, Joanna Kopecka, et al.
Current Drug Metabolism|October 16, 2008
Classical inhibitors of NOX NAD(P)H oxidases are not specificElisabetta Aldieri, Chiara Riganti, Manuela Polimeni, et al.
Oncotarget|December 30, 2014
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesotheliomaIris Chiara Salaroglio, Ivana Campia, Joanna Kopecka, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|July 16, 2013
Insights in the chemical components of liposomes responsible for P-glycoprotein inhibitionJoanna Kopecka, Giuseppina Salzano, Ivana Campia, et al.
Oncotarget|February 18, 2015
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cellsJoanna Kopecka, Ivana Campia, Andrea Jacobs, et al.
Pageof 3